Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

May 16, 2022, 6:43 a.m. EDT

Chimerix stock surges after deal to sell smallpox treatment Tembexa for up to $337.5 million, plus royalties

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Chimerix Inc. (CMRX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Chimerix Inc. /zigman2/quotes/209385333/composite CMRX +0.98% shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to $337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open. Under terms of the deal, Chimerix will receive $225 million and up to $100 million in milestone payments. Chimerix could also receive $12.5 million in regulatory milestones, and could also earn a 20% royalty on future gross profit of Tembexa in the U.S. and a 15% royalty on gross profit for Tembexa sales during the exclusivity period. "This transaction significantly enhances Chimerix's balance sheet and allows us to focus and invest in our development pipeline," said Chimerix Chief Executive Mike Sherman. Chimerix shares have tumbled 34.1% year to date through Friday and Emergent's stock has dropped 33.9%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.07% has declined 15.6%.

/zigman2/quotes/209385333/composite
US : U.S.: Nasdaq
$ 2.06
+0.02 +0.98%
Volume: 4.48M
June 29, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$178.37 million
Rev. per Employee
$6,425
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,818.83
-2.72 -0.07%
Volume: 2.11B
June 29, 2022 5:16p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.